Implementation of innovative technology for the production of high-purified protein lyazox of chicken protein, as an opportunity for the development of veterinary and human medicine. (Q134596): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item)
(‎Removed claim: summary (P836): In recent times, immunology is growing rapidly. Lysozyme (DL) is an effective substance for the treatment of a number of animal diseases of bacterial and viral origin, which also has its anti-incendiary properties. the project has a very high market potential arising from: (1) effective treatment of DL — the active substance of the DVO (veterinary medicinal product) admitted to trading in Poland under the name of Lydium-KLP, for horses, cows a...)
Property / summary
In recent times, immunology is growing rapidly. Lysozyme (DL) is an effective substance for the treatment of a number of animal diseases of bacterial and viral origin, which also has its anti-incendiary properties. the project has a very high market potential arising from: (1) effective treatment of DL — the active substance of the DVO (veterinary medicinal product) admitted to trading in Poland under the name of Lydium-KLP, for horses, cows and pigs (2), as well as for the treatment of other animal species (including: goats, sheep, dogs and cats) (3) the potential of the market (number of animals) (4) satisfactory results of research on the use of DL in human medicine (now the second stage of the clinical trial) (5), the lack of a highly purified DL (6) market absence from the market for the trend in animals growing for the greening of the process (e.g. by the elimination of antibiotics), the scope of the project is determined by the nature of the product — the pharmaceutical substance, subject to the complex procedures which must be submitted to the market as the active substance of the DVO. The project consists of the acquisition, by the Applicant, of an exclusive right to innovative technology for the production of high-purified liquor egg white hen egg in industrial scale. It is, therefore, the subject of the project to acquire intangible assets in the form of a licence and a technical documentation attached to it which describes the production process of the Lyuomus.PLANATED EFESC process: (1) Number of enterprises receiving support: 1; receiving grants: 1; supported to introduce new market products: 1; supported to introduce new business products: 1 (2) Private investment — complementary public support to enterprises (grants): PLN 74 976,00; complementary public support for innovation or R & D projects: 0PLN (3) Number of intangible assets acquired: 1 (English)
 
Property / summary: In recent times, immunology is growing rapidly. Lysozyme (DL) is an effective substance for the treatment of a number of animal diseases of bacterial and viral origin, which also has its anti-incendiary properties. the project has a very high market potential arising from: (1) effective treatment of DL — the active substance of the DVO (veterinary medicinal product) admitted to trading in Poland under the name of Lydium-KLP, for horses, cows and pigs (2), as well as for the treatment of other animal species (including: goats, sheep, dogs and cats) (3) the potential of the market (number of animals) (4) satisfactory results of research on the use of DL in human medicine (now the second stage of the clinical trial) (5), the lack of a highly purified DL (6) market absence from the market for the trend in animals growing for the greening of the process (e.g. by the elimination of antibiotics), the scope of the project is determined by the nature of the product — the pharmaceutical substance, subject to the complex procedures which must be submitted to the market as the active substance of the DVO. The project consists of the acquisition, by the Applicant, of an exclusive right to innovative technology for the production of high-purified liquor egg white hen egg in industrial scale. It is, therefore, the subject of the project to acquire intangible assets in the form of a licence and a technical documentation attached to it which describes the production process of the Lyuomus.PLANATED EFESC process: (1) Number of enterprises receiving support: 1; receiving grants: 1; supported to introduce new market products: 1; supported to introduce new business products: 1 (2) Private investment — complementary public support to enterprises (grants): PLN 74 976,00; complementary public support for innovation or R & D projects: 0PLN (3) Number of intangible assets acquired: 1 (English) / rank
Normal rank
 

Revision as of 17:52, 21 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Implementation of innovative technology for the production of high-purified protein lyazox of chicken protein, as an opportunity for the development of veterinary and human medicine.
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    43,104.0 zloty
    0 references
    10,344.96 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    96,000.0 zloty
    0 references
    23,040.0 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    44.9 percent
    0 references
    start time
    24 February 2017
    0 references
    end time
    30 August 2017
    0 references
    beneficiary name (string)
    GRZEGORZ NOWAK REMEDIA VETERINARIA-BADANIA I KONSULTING LEKARSKO-WETERYNARYJNY SKRÓT :REMEDIA VETERINARIA
    0 references
    beneficiary
    Q2538961
    0 references
    summary
    W ostatnim czasie szczególnie dynamicznie rozwija się immunologia weterynaryjna. Dimer lizozymu (DL) to substancja skuteczna w leczeniu wielu schorzeń zwierząt o pochodzeniu bakteryjnym i wirusowym, posiadająca też właściwości przeciwzapalne.Opisywany projekt ma bardzo wysoki potencjał rynkowy wynikający z:(1) skuteczności leczenia DL - substancją aktywną PLW (produktu leczniczego weterynaryjnego) dopuszczoną do obrotu na terenie RP pod nazwą Lydium-KLP dla koni, krów i świń(2) wyników badań wskazujących skuteczność DL także w przypadku leczenia innych gatunków zwierząt (w tym: kóz, owiec, psów i kotów)(3) potencjału rynku (liczebność pogłowia zwierząt)(4) zadowalających wyników badań nad wykorzystaniem DL w medycynie ludzkiej (obecnie II etap badań klinicznych)(5) braku na rynku wysokooczyszczonej postaci DL(6) siły trendów w hodowli zwierząt dążących do ekologizacji procesu (np. poprzez eliminację antybiotyków) Zakres projektu determinowany jest charakterem produktu - substancji farmaceutycznej, podlegającej złożonym procedurom, warunkującym jej dopuszczenie do rynku, jako substancji czynnej PLW. Projekt polega na nabyciu przez Wnioskodawcę wyłącznego prawa do innowacyjnej technologii produkcji wysokooczyszczonego dimeru lizozymu białka jaja kurzego na skalę przemysłową. Stąd przedmiotem projektu jest nabycie wartości niematerialnych i prawnych w postaci licencji i dołączonej doń dokumentacji technicznej, zawierającej opis procesu produkcyjnego dimeru lizozymu.PLANOWANE EFEKTY RZECZOWE:(1) Liczba przedsiębiorstw - otrzymujących wsparcie: 1; otrzymujących dotacje: 1; objętych wsparciem w celu wprowadzenia produktów nowych dla rynku: 1; objętych wsparciem w celu wprowadzenia produktów nowych dla firmy: 1(2) Inwestycje prywatne - uzupełniające wsparcie publiczne dla przedsiębiorstw (dotacje): 74 976,00 PLN; uzupełniające wsparcie publiczne w projekty w zakresie innowacji lub badań i rozwoju: 0PLN(3) Liczba nabytych wartości niematerialnych i prawnych: 1 (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    RPWP.01.05.02-30-0498/15
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q134596&oldid=6542688"